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Obstetric haemorrhage (OH) is the leading cause of maternal deaths 
worldwide, accounting for 25 - 30% of all such deaths, especially in 
low- to middle-income countries.[1] Non-pregnancy-related infect-
ions, where HIV is a major contributing factor, are the major cause 
of maternal deaths in sub-Saharan African countries, including 
South Africa (SA).[2] However, as this is an indirect cause, OH and 
hypertensive disorders of pregnancy (HDPs) are therefore the most 
common direct causes of maternal deaths.[2] In the initial SA triennial 
reports on maternal deaths, HDP was the overall leading cause of 
death and the leading cause of direct deaths. However, subsequently, 
HIV-related causes were predominantly in the lead. In SA, where 1 
in 3 pregnant women are HIV infected,[3] the number of such deaths 
are now decreasing as a result of the successful use of combination 
antiretroviral treatment (cART), and consequently direct causes such 
as OH are beginning to emerge. An increase in OH, which mostly 
occurs at caesarean section, has already been shown in the last two 
triennial reports on maternal deaths.[3,4]
Pregnancy is a prothrombotic state, and in studies of adult patients, 
HIV has also been shown to be prothrombotic and may also be associated 
with deep vein thrombosis and thrombotic cerebrovascular accidents.[5] 
However, HIV is also associated with anaemia and thrombocyto-
penia.[6] While there is a direct effect on haemostasis with the latter 
condition, anaemia has been cited as a risk factor for OH-associated 
morbidity.[6,7] HIV-infected women with advanced disease may 
have some form of chorioamnionitis, which may result in excessive 
postpartum haemorrhage (PPH). Subclinical chorioamnionitis may 
lead to higher rates of abruptio placentae, but also to poor postpar-
tum contractility of the uterus.[8] It would be expected that with the 
widespread use of antiretro viral treatment, these effects would be 
reversed. Recently, an association between HIV infection and OH has 
been reported.[9,10] A closer look at the SA triennial reports show that, 
for the first time, there was an increased number of deaths from OH 
in the 2008 - 2010 report (and subsequent ones), 200 more than that 
recorded in the previous triennial reports of 2002 - 2004 and 2005 - 
2007.[4] This increase coincided with the introduction of cART among 
HIV-infected pregnant women, whereas previously, single-dose 
nevirapine (sdNVP) was administered. Against this background, we 
hypo thesised that the increasing haemorrhage, as reported among 
maternal deaths, may be related to HIV or its treatment. We aimed to 
study this, using the available data.
Our study determined the prevalence of OH during the different 
phases of the changing drug regimen for the prevention of mother-
to-child transmission (PMTCT). 
Methods
We conducted a retrospective chart review of all recorded cases that 
had some form of OH at King Edward VIII Hospital, Durban, SA, 
from 1 January 2009 to 31 December 2011. About 500 - 600 neo-
nates are delivered monthly at this large regional hospital. During 
this period, a number of changes were introduced with regard to 
antiretroviral drugs used in the PMTCT programme, including 
sdNVP (before 2008), and subsequently dual therapy (i.e. antenatal 
zidovudine from 28 weeks of gestation, intrapartum sdNVP for 
women with CD4 counts >200 cells/µL, and cART for those whose 
CD4 counts were <200 cells/µL). By the end of 2009, dual therapy 
was initiated from 14 weeks of pregnancy, and women were eligible 
for cART if their CD4 counts were <350 cells/µL. During the study 
period, cART consisted of stavudine, lamivudine and nevirapine.
We searched delivery records, theatre records and admissions to 
the high-care unit for the diagnosis of any form of OH. A case of 
OH was established if a record indicated a diagnosis of antepartum 
haemorrhage (APH) (unspecified), abruptio placentae, ruptured 
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uterus, or retained placenta, bleeding after trauma to the lower 
genital tract, symptomatic placenta praevia, and PPH. We reviewed 
in-patient records of all identified and available cases and of those 
who had a blood transfusion (also in the case of a vaginal birth or 
any procedure for manual removal of the placenta) to determine if 
a diagnosis of APH or PPH was recorded. Data regarding patient 
demographics, obstetric complications and HIV status were entered 
into a Microsoft Excel spreadsheet and exported to SPSS 
version 21 (IBM Corp., USA) for analysis. Continuous variables 
were summarised using means, standard deviations (SDs) and odds 
ratios (ORs). Significant associations were identified using Fisher’s 
exact test or the standard Pearson χ2 test. Statistical significance was 
assessed at p<0.05.
The study was approved by the Biomedical Research Ethics 
Committee (ref. no. BE270/12) and King Edward VIII Hospital 
administration (ref. no. KE2/7/1/01/2013). As this was a retrospective 
study, informed consent was not obtained. 
Results
According to the different registers used, 582 patients were diag-
nosed with some form of OH or with blood transfusion during the 
3 years of the study. Fifty-four files of patients listed as OH cases 
could not be located. Fifty-seven, who were listed to have some 
form of OH, could also not be found, but this was not recorded in 
the patient file. Another 37 patients had been transfused for anae-
mia not associated with haemorrhage and were therefore excluded. 
Finally, data from 448 patient files were reviewed. During the study 
period, there were 19 953 deliveries in the hospital, with an inci-
dence of 2.25% for OH. Thirty-four percent (n=153) of these were 
HIV-infected, 57.6% (n=258) HIV-uninfected, and in 8.3% (n=37) 
HIV was not recorded or HIV status was unknown. 
The study found that as the PMTCT regimen evolved to include 
more drugs introduced at an earlier stage of gestation, the total 
number of OH cases increased with each year studied (Fig. 1). The 
annual incidence of OH was 1.63%, 2.49% and 2.61% for 2009, 
2010 and 2011, respectively (p<0.0001). This increasing incidence 
coincided with the changing regimen of PMTCT in 2008 - 2009, 
from the administration of zidovudine at 28 weeks to a much earlier 
gestation at 14 weeks (Fig. 1). Parallel with this change, there was 
also an increase in the CD4 count threshold for the admin istration 
of cART, where women with CD4 counts of <350 cells/µL (not <200 cells/
µL) were now eligible for cART, i.e more women were now recei-
ving cART. 
The most common condition among OH patients was abruptio 
placentae (n=271, 60.5%), followed by PPH (n=125, 27.9%). The 
latter followed unspecified APH in 69 women. In the remaining 
women, PPH was secondary to a retained placenta (n=14), uterine 
atony (n=27) and lower genital tract tears, including a ruptured 
uterus (n=15). The most common risk factor for abruptio placen-
tae was HDP (including chronic hypertension and pre-eclampsia) 
(n=73, 26.9%), while a significant proportion had no risk factors 
(n=76, 28%). Unspecified APH accounted for 16.9% (n=76), pos-
sibly due to minor degrees of abruptio placentae. Placenta praevia 
accounted for 10.1% (n=45) of cases (Table 1). 
Of the 153 HIV-infected women, 24.8% (n=38) were on sdNVP, 
69 (45.1%) received dual therapy, and 46 (30.1%) were on cART. 
The mean CD4 counts were 395 (range 50 - 1 000) cells/µL, 417 
(177 - 720) cells /µL, and 273 (131 - 980) cells/µL for women recei-
ving sdNVP, dual therapy and cART, respectively. Whereas HIV was 
associated with an increased risk of PPH (p=0.007), Table 2 shows no 
statistically significant association between OH and HIV treatment.
The proportion of women who developed abruptio placentae and 
unspecified APH was similar for HIV-infected (77.1%) and HIV-
uninfected (74.8%) patients (p=0.596). In the HIV-infected group, 
there was no difference in the risk of abruptio placentae, unspeci-
fied APH and PPH between those who received highly active 
antiretroviral therapy (HAART) and those who received fewer than 
three drugs (i.e. sdNVP or dual therapy) (p=0.123, p=0.834 and 
p=0.901, respectively). 
Maternal and perinatal outcomes
The mean (SD) age of the patients was 26.3 (6.325) years, with a 
parity of 1±1 (0 - 6) – HIV-infected women being slightly older 
(p=0.004) (Table 1). The gestational age at delivery was lower among 
HIV-infected women and those with unknown HIV status (p=0.005). 
Thirty-six percent of women delivered at <34 weeks, and 30% at or 
beyond 38 weeks of gestation, but these differences did not differ 
according to HIV status. 
The mean haemoglobin (Hb) at baseline was 9.17 (2 - 16) g/dL, 
and was significantly lower among HIV-infected (8.6 g/dL) compared 
with HIV-uninfected (9.62 g/dL) patients (p=0.006). Similarly, there 
were more women with anaemia (Hb <11 g/dL) among HIV-infected 
than HIV-uninfected women (p=0.000). 0verall, 40.3% (n=178) of 
women required transfusion, receiving a mean of 2.8 U of packed cells, 
with more HIV-infected than HIV-uninfected women being trans-
fused (p=0.045). The caesarean section rate was high (n=326, 72.6% ); 
however, it was similar in both groups (HIV-uninfected (76.6%) and 
HIV-infected (69.9%)) (p=0.133). PPH occurred at or after caesarean 
section in 40.8% (n=40) of cases. This difference of fewer caesarean 
sections among PPH cases compared with the entire group with OH 
was statistically significant (relative risk = 0.5, 95% confi dence interval 
(CI) 0.39 - 0.64).
There were four maternal deaths among HIV-infected women, 
two of whom were receiving cART. They died in the intensive care 
unit (ICU) from hypovolaemic shock, subsequent disseminated 
intravascular coagulation and multi-organ failure – secondary to 
placenta praevia (n=1), PPH at caesarean section for fetal distress and 
cephalopelvic disproportion (with no other risk factors, n=2), and 
caesarean section for abruptio placentae (n=1). Furthermore, those 
who survived suffered severe morbidity, such as transfusion, renal 
Fig. 1. Increased obstetric haemorrhage with changing of the prevention of 
mother-to-child programme. In April 2008 cART was introduced for women 
with a CD4 count of <200 cells/µL. In 2009 zidovudine was introduced 
from 28 weeks for those with a CD4 count of >200 cells/µL. In 2010 the 
CD4 threshold increased to <350 cells/µL and zidovudine was started from 
14 weeks. (APH = antepartum haemorrhage; PPH = postpartum haemorr-
hage; sdNVP = single-dose nevirapine; cART = combination antiretroviral 
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failure, hysterectomy and ICU admission. 
The mortality risk, hysterectomy and ICU 
admission were all significantly associated 
with HIV-sero positive status (Table 1). 
There were 365 (81.5%) live births, with 
69 stillbirths (18.5%) and 14 early neonatal 
deaths. The perinatal mortality rate was 
much higher among HIV-infected patients 
(248/1 000 births) compared with HIV-
uninfected patients (159/1 000) (p=0.031). 
Discussion
We found that HIV increased the risk of 
PPH, but not of any form of APH. This is in 
keeping with the findings of Curtis et al.,[9] 
who showed an association between severe 
OH and positive HIV serostatus. However, 
Calvert and Ronsmans,[10] in a systematic 
review and meta-analysis, reported no 
increased odds of PPH from 13 studies, but 
twice the odds of APH. As mentioned above, 
the total number of haemorrhage cases per 
year increased significantly over the same 
period, during which more drugs were being 
added to the PMTCT regimen. We could, 
however, not demonstrate any significant 
association with the use of cART in any of 
the categories examined. It is also worth 
noting that the clinical implementation of 
the changing guidelines often lagged behind, 
and it is therefore difficult to make direct 
associations. In a secondary analysis of the 
data from the Saving Mothers Report of 2014, 
there was an increased risk of OH associated 
with both HIV infection and its treatment,[11] 
but this was not so in the current study. 
The possible association between HIV 
and PPH is probably due to haemostatic fac-
tors or poor uterine contractility, as vascular 
factors at the uteroplacental interface would 
probably manifest with a higher occurrence 
of APH (e.g. abruptio placentae). Further 
studies are needed in this regard. 
The prevalence of OH in our study was 
lower than that in other studies, which was 
unexpected, given the background reports. 
APH was 1.97% and PPH 0.63%. Both these 
figures are lower than those quoted in other 
studies (APH 3 - 5%[12] and PPH 5 - 13%[13]), 
despite the local figures of increasing num-
bers of both conditions among maternal 
deaths, particularly PPH after caesarean sec-
tion.[4] Lombaard and Pattinson[14] recorded 
a higher PPH incidence of 8 - 9% in their 
report of near misses among a popula-
tion similar to that in the current study. 
We do not believe that this is an under-
representation of the conditions examined, 
as we screened records from all the relevant 
sectors in the maternity sections. It is pos-
sible that there was under-reporting of 
PPH cases at vaginal delivery; however, 
this was probably clinically insignificant, 
as these cases would have been reported 
under blood transfusions. The caesarean 
section rate in the current cohort was high 
(>70%), which is understandable, as most 
causes of APH (placenta praevia, abruptio 
placentae with a live baby, and unclassified 
APH) require delivery by caesa rean sec-
tion. PPH after caesarean section occurred 
in only 40% of cases – the normal rate for 
this regional hospital. According to SA 
reports, there was an increase of 28% in the 
deaths from bleeding after caesarean sec-
tion between 2011 and 2012 (27.5 - 35.3%). [2,4] 
It may be that in the majority of women who 
die of PPH the condition occurs during 
caesarean section. It may mean that the 
estimation of blood loss is inaccurate in 
these circumstances or, alternatively, that 
the resuscitative measures are insufficient 
or instituted too late. The poor estimation 






Age, mean (SD) 25.19 (5.84) 27.72 (6.18) 0.000
Parity, mean (SD) 0.92 (0.97) 1.21 (1.07) 0.014
Gestational age at delivery, mean (SD) 35.5 (4.0) 34.5 (4.1) 0.001
Hb (g/dL), mean (SD) 9.62 (3.16) 8.58 (3.81) 0.006
  Hb <11 g/dL, mean (SD) 140.0 (54.5) 113.0 (73.8) <0.001
Platelets, mean (SD) 171.4 (108.0) 155.9 (112.8) 0.306
Obstetric haemorrhage
Abruptio placentae, n (%) (n=271) 151 (58.8) 94 (61.4) 0.592
APH, n (%) (n=76) 42 (16.3) 24 (15.7) 0.596
Placenta praevia, n (%) (n=45) 31 (12.1) 11 (7.2) 0.116
PPH, n (%) (n=125) 55 (21.4) 51 (33.3) 0.007
Maternal outcome
Caesarean section, n (%)  19 (76.6) 107 (69.9) 0.133
Hysterectomy, n (%)  6 (2.3) 11 (7.2) 0.017
ICU admission, n (%) 1 (0.39) 11 (7.2) <0.001
Maternal death, n (%) 0 4 (2.6) <0.001
Neonatal outcomes
Stillbirth, n (%) 34 (13.2) 25 (16.3) 0.895
ENND, n (%) 7 (2.7) 7 (4.6) 0.318
Perinatal mortality rate, n (%) 158.9/1 000 248.4/1 000 0.031
Hb = haemoglobin on admission; SD = standard deviation; APH = antepartum haemorrhage; PPH = postpartum haemorrhage; 
ICU = intensive care unit; ENND = early neonatal death.












cART v. no cART
Abruptio placentae, n (%) (n=271) 151 (58.8) 25 (65.8) 45 (65.2) 24 (52.2) 0.123
Unspecified APH, n (%) (n=76) 42 (16.3) 2 (5.2) 12 (17.4) 10 (21.7) 0.177
Placenta praevia, n (%) (n=45) 31 (12.1) 2 (5.2) 6 (8.7) 3 (6.5) 0.834
PPH, n (%) (n=125) 55 (17.1) 18 (47.3) 18 (26.1) 15 (32.6) 0.901
APH = antepartum haemorrhage; PPH = postpartum haemorrhage; sdNVP = single-dose nevirapine; cART = combination antiretroviral therapy. 
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of blood loss may account for the lower prevalence of PPH after 
vaginal deliveries. 
We found that HIV-infected women had significantly lower Hb 
values at the time of admission, with more of these women receiving 
blood transfusions. Bloch et al.,[15] in a large SA study, showed an 
increased risk of transfusions with blood products among HIV-
infected pregnant women compared with HIV-uninfected women 
(3.7% v. 2.4%) (adjusted OR 1.52; 95% CI 1.14 - 2.03). 
As can be expected, maternal morbidity from haemorrhage (e.g. 
in hysterectomy and maternal deaths) was higher in HIV-infected 
women, with a similar trend observed in perinatal outcomes. The 
latter showed higher rates of both stillbirths and early neonatal deaths 
in HIV-infected women, with an overall increased perinatal mortality 
rate among these women. The perinatal mortality rate was also 
increased among HIV-infected women (three times higher than the 
local figure (Ati MA, et al. – unpublished data) and probably related 
to abruptio placentae (>50% in the study population). 
Study limitations
The study is limited by its retrospective nature, and some of the 
vital information, such as CD4 counts, was missing. The lack of 
control for CD4 counts, and the study being underpowered to show 
the differences according to the use of cART among HIV-infected 
women, are also noted as limitations. Both these are important areas 
to pursue in further research, as the ongoing monitoring of drug 
adverse effects is important. 
Conclusion
The results of the current study add to the body of emerging 
reports that indicate a higher rate of OH in HIV-infected women. 
Even though there was originally an apparent increased risk of 
haemorrhage with the introduction of HIV treatment, this was not 
statistically ascertained in our study. An underlying mechanism 
could not be determined in our analysis; it therefore calls for further 
research to confirm the abovementioned findings and possible 
associated causes. 
Recommendations
Reducing the number of deaths from OH is a priority worldwide, 
and the possible association between PPH and HIV makes it even 
more urgent. With the cART programme continuously evolving and 
the use of new drugs being introduced, it is important to continue 
monitoring adverse events. 
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